GENENTECH, INC for GENENTECH INC

Trade (domestic/foreign) TRD

Trade negotiations and Transatlantic Trade Partnership (TTIP). Issues related to trade policy.

Contacted: Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA)

Taxation/Internal Revenue Code TAX

Issues related to corporate tax reform. General Tax Issues.

Contacted: Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Executive Office of the President (EOP)

Copyright/Patent/Trademark CPT

Intellectual Property and Process Patent Issues. Patent Litigation Reform.

Contacted: Executive Office of the President (EOP); Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Pharmacy PHA

Monitor Drug Safety and pedigree legislation. 340B Drug Discount Program.

Contacted: SENATE; Food & Drug Administration (FDA); Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Medical/Disease Research/Clinical Labs MED

Bioterrorism preparedness and development of medical countermeasures.

Contacted: Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

Provide guidance and strategic counsel with regard to regulations and legislation that could impact, pharmaceutical and biotechnology manufacturers. Policies related to the 340B Drug Discount Program. Drug pricing issues. HR 1628, The American Health Care Act. S. 469 Affordable and Safe Prescription Drug Importation Act. Prescription Drug User Fee Act Agreements. S.204/H.R.878, Trickett Wendler Right to Try Act of 2017. Issues related to the implementation of the follow-on biologics provisions in P.L. 111148 "Patient Protection and Affordable Care Act". Stockpiling of medical countermeasures in advance of a potential pandemic. Implementation of issues related to the Security and Accountability Act (P.L. 113-54); Issues related to Pharma supply chain.

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); SENATE; Food & Drug Administration (FDA)

Bills named: H.R. 1628 (115th), H.R. 878 (115th), S. 469 (115th), S. 204 (115th)

Medicare/Medicaid MMM

Implementation of Medicare pharmaceutical coverage and reimbursement issues; Medicare Part B reimbursement for physicians and implementation of related provisions of the Affordable Care Act; reimbursement adequacy and patient access issues associated with potential CMMI implementation of the proposed Medicare Part B drug payment model. Policies relating to 340B Program. Issues relating to the repeal and replacement of the Affordable Care Act (HR 1628, The American Health Care Act).

Contacted: HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); SENATE; Food & Drug Administration (FDA)

Bills named: H.R. 1628 (115th)

Budget/Appropriations BUD

Issues related to FDA and HHS program funding in the FY17 Labor, Health and Human Services, and Education and Related Agencies, and FY17 Agriculture, Rural Developments, Food and Drug Administrations, and Related Agencies Appropriations bills.

Contacted: Food & Drug Administration (FDA); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)